Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 17:28:18 Source:styleViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Mohammad Mokhber: Who is Iran’s acting president?
Next:Company wins court ruling to continue development of Michigan factory serving EV industry
You may also like
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
- Westwood, Kahlina guide Charlotte to 1
- Finnish carrier will resume Estonia flights in June after GPS interference prevented landings
- New Kansas abortion clinic will open to help meet demand from restrictive neighboring states
- Liverpool confirms Arne Slot as Jurgen Klopp's replacement
- Australian gov't confirms 2nd consecutive budget surplus
- Rory McIlroy's ex
- Just Stop Oil eco
- Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk